Flat-panel developer ordered to resume productionThe future of digital detector component supplier Optical Imaging Systems (OIS) remains unknown following a directive from the U.S. Department of Commerce ordering the company to resume production
Flat-panel developer ordered to resume production
The future of digital detector component supplier Optical Imaging Systems (OIS) remains unknown following a directive from the U.S. Department of Commerce ordering the company to resume production of thin-film transistor arrays. The deal gives some breathing room to those companies to which OIS ships the arrays, such as Sterling Diagnostic Imaging, which uses OIS components in its DirectRay digital radiography systems.
OIS of Northville, MI, announced last month that it was shutting down after its parent company, Guardian Industries, cut off funding to the subsidiary (SCAN 9/30/98). OIS had been trying to find a buyer or investor since earlier this year, but was unsuccessful.
The Department of Commerce stepped in because OIS was the only qualified U.S. manufacturer of the high-resolution flat-panel screens used in several U.S. military systems, including the F-16 advanced fighter aircraft, the Apache attack helicopter, and the M-1 Abrams tank. The DOC issued the order under the Defense Production Act and the Selective Service Act, which authorize the president to take steps to assure the availability of goods considered vital to national defense.
The DOC said that civil injunction or criminal penalties may be imposed for failure to comply with the order, which is contingent upon the availability of funding for OIS. Current OIS customers have agreed to fund OIS until another solution for the company is found, however.
The government's order does not appear to have had much impact yet. On Oct. 1, OIS executives met with Commerce Department officials in Washington, DC, to discuss ways to reopen the plant. But neither OIS president Rex Tapp nor Assistant Commerce Secretary Roger Majak would say how OIS could restart production, according to an Oct. 2 article in the Detroit Free Press. Sterling representatives are closely monitoring the talks.
"As of (Oct. 6), we believe that they have not opened
their doors yet, but as far as we know, discussions are continuing between DOC, DOD, OIS, and its customers," said Jayne Seebach, Sterling's director of global marketing and communications.
Sterling remains optimistic that a new operator will acquire the assets of OIS and continue supply from its facilities, said Ernest Waaser, Sterling COO. A consortium of OIS customers has made viable offers to purchase certain assets of OIS, he said. OIS declined to return calls seeking comment.
In any event, Sterling continues to move forward with discussions with other companies about potential TFT array supply relationships and is moving to begin the qualification process to ensure that components from these companies meet Sterling's criteria. The qualification process for another supplier typically takes six to 12 months, although Sterling would expedite that process as much as possible, Seebach said.
The Greenville, SC-based company has enough TFT arrays to meet its product needs through the end of the year and believes that several hundred arrays are in the development process at OIS. Sterling is working with OIS to confirm the number and production status of the arrays, as well as to complete as many in-process arrays as possible.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.